June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Arndt Vogel Highlights HEPATORCH Trial Results Comparing Toripalimab Plus Bevacizumab with Sorafenib in Advanced HCC
Jun 6, 2025, 07:49

Arndt Vogel Highlights HEPATORCH Trial Results Comparing Toripalimab Plus Bevacizumab with Sorafenib in Advanced HCC

Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a post on X:

“Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
HEPATORCH phs 3 trial
  • supports anti-VEGF and ICI combinations
  • Inline with IMbrave150, CARES-310 and ORIENT-32

Title: Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial

Authors: Yinghong Shi, Guohong Han, Jian Zhou, Xuetao Shi, Weidong Jia, Ying Cheng, Yongdong Jin, Xiangdong Hua, Tianfu Wen, Jianbing Wu, Shanzhi Gu, Yuxian Bai, Xiangcai Wang, Tao Zhang, Zhiyu Chen, Bixiang Zhang, Ming Huang, Hongming Liu, Yilei Mao, Ledu Zhou, Rui Wang, Yunfeng Shan, Wu Zhang, Tianqiang Song, Yabing Guo, Fuxiang Zhou, Bingfeng Shao, Mingjun Zhang, Bo Liang, Jinfang Zheng, Guoping Zhang, Jie Shen, Weiwen Su, Feng Zhang, Yifu He, Sheng Hu, Rong Liu, Chengwu Zhang, Shunli Shen, Hui Zeng, Tsang-En Wang, Wenzhi Guo, Yan Shen, Yajin Chen, Yong Li, J Samol, Hongtao Hu, Wenhua Zhang, Chengyou Du, Enxiao Li, Chao Liu, Choo Su Pin, Xun Li, Hao Xu, Jee-Fu Huang, Chunyi Hao, Jing Lv, Wei Wang, Qian Xu, Aobing Bai, Xiao Zhang, Bifeng Liu, Chunlei Jin, Jia Fan

You can read the Full Article on The Lancet Gastroenterology and Hepatology

Arndt Vogel

More posts featuring Arndt Vogel.